These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6648238)

  • 1. Activators and inhibitors of the fibrinolytic system in maturity-onset diabetes mellitus without thromboembolic manifestations.
    Gamba G; Grignani G; Montera V; Perotti G; Ragone L; Ascari E
    Ric Clin Lab; 1983; 13(3):337-45. PubMed ID: 6648238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fibrinolytic system in patients with myocardial infarction and other coronary disease risk factors].
    Moreno JA; Gálvez MM; Cornudella R; Angós JA; Romero MS; Gutiérrez M
    Sangre (Barc); 1994 Apr; 39(2):111-6. PubMed ID: 8059288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoglycemic treatments and the fibrinolytic system in maturity-onset diabetes mellitus without thromboembolic manifestations.
    Gamba G; Grignani G; Biancardi M; De Marco R; Grassi M; Ferrari E
    Acta Diabetol Lat; 1983; 20(1):63-70. PubMed ID: 6858544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced antithrombotic mechanisms in patients with maturity-onset diabetes mellitus without thromboembolic complications.
    Grignani G; Gamba G; Geroldi D; Pacchiarini L; Solerte B; Ferrari E; Ascari E
    Thromb Haemost; 1981 Oct; 46(3):648-51. PubMed ID: 6797094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
    Aso Y; Wakabayashi S; Yamamoto R; Matsutomo R; Takebayashi K; Inukai T
    Diabetes Care; 2005 Sep; 28(9):2211-6. PubMed ID: 16123492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activators and antiplasmin activity in atopic dermatitis.
    Lotti T; Battini ML; Brunetti L; Fabbri P; Panconesi E
    Int J Dermatol; 1989 Sep; 28(7):457-9. PubMed ID: 2777445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severity of coronary artery disease and basal fibrinolysis.
    Small M; Lowe GD; Beattie JM; Hutton I; Lorimer AR; Forbes CD
    Haemostasis; 1987; 17(5):305-11. PubMed ID: 2444504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus.
    Auwerx J; Bouillon R; Collen D; Geboers J
    Arteriosclerosis; 1988; 8(1):68-72. PubMed ID: 2449156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of hyperlipoproteinemia on blood fibrinolytic activity and thrombocyte aggregation].
    Kostić N; Secen S
    Med Pregl; 2000; 53(3-4):180-3. PubMed ID: 10965685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men.
    Glueck CJ; Glueck HI; Stroop D; Speirs J; Hamer T; Tracy T
    J Lab Clin Med; 1993 Oct; 122(4):412-20. PubMed ID: 8228555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus.
    Morishita E; Asakura H; Jokaji H; Saito M; Uotani C; Kumabashiri I; Yamazaki M; Aoshima K; Hashimoto T; Matsuda T
    Atherosclerosis; 1996 Feb; 120(1-2):7-14. PubMed ID: 8645373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [ Fibrinolysis in diabetes mellitus].
    Syrbe G; Jütte A; Wittwer E; Deufrains A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(3):317-28. PubMed ID: 2428706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertriglyceridemia, but not hypercholesterolemia, is associated with the alterations of fibrinolytic system.
    Hiraga T; Shimada M; Tsukada T; Murase T
    Horm Metab Res; 1996 Nov; 28(11):603-6. PubMed ID: 8960902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of spontaneous fibrinolytic activity in diabetic retinopathy.
    Ostermann H; Tschöpe D; Greber W; Meyer-Rüsenberg HW; van de Loo J
    Thromb Haemost; 1992 Oct; 68(4):400-3. PubMed ID: 1448770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Euglobulin fibrinolytic activity in NIDDM patients.
    Cho YW; Oh DY; Kim SJ; Hong SY; Lee HC; Huh KB
    Diabetes Res Clin Pract; 1991 Sep; 13(3):139-45. PubMed ID: 1959478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofibrinolysis associated with vasculopathy in non insulin dependent diabetes mellitus.
    García Frade LJ; de la Calle H; Torrado MC; Lara JI; Cuellar L; García Avello A
    Thromb Res; 1990 Jul; 59(1):51-9. PubMed ID: 2119076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On fibrinolysis in diabetes mellitus.
    Almér LO; Nilsson IM
    Acta Med Scand; 1975; 198(1-2):101-6. PubMed ID: 52286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinolysis and diabetic retinopathy.
    Almér LA; Pandolfi M
    Diabetes; 1976; 25(2 SUPPL):807-10. PubMed ID: 61139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinolytic capacity following stimulation with desmopressin acetate in patients with diabetes mellitus.
    Grant MB; Fitzgerald C; Guay C; Lottenberg R
    Metabolism; 1989 Sep; 38(9):901-7. PubMed ID: 2505017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Contact (prekallikrein) and fibrinolytic (plasminogen/antiplasmin value) system in the physiopathology of vascular complications of diabetes].
    Janody D; Droulle C; Adjizian JC; Ostermann G; Poynard JP; Jeunehomme G; Leutenegger M; Potron G
    J Mal Vasc; 1982; 7(3):221-4. PubMed ID: 6815291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.